Nonetheless, given their functional relevance across key metabolic tissues and their regulatory roles throughout the spectrum of metabolic disease, both RKIP and YY1 represent viable and compelling targets for therapeutic intervention in obesity and T2D. The gene discussed is PEBP1; the disease is obesity due to melanocortin 4 receptor deficiency.